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Oral Presentations S175Results: Eleven inpatient HSCT recipients were diagnosed with
probable/proven H1N1 influenza in our two centers. Ten had un-
dergone allogeneic HSCT and one had undergone autologous
HSCT. Eight of the 10 allogeneic recipients had either active or
prior GVHD, and 6 were on./5 20 mg of prednisone. The diagno-
sis of S-OIV was made 12 -1000 (median 355) days after HSCT.
Three patients had suspected noscomial infection. Clinical presenta-
tions were diverse, ranging from atypical (febrile/neutropenia with-
out respiratory tract symptoms) to mild (low grade fever and mild
cough) to classic influenza symptoms (high fever, chills, sore throat,
myalgias, cough, headache and nasal congestion). Severity of pre-
senting symptoms did not correlate with outcome; however, hypox-
emia and lower tract disease at diagnosis were predictive of poor
outcomeTwo of 8 rapid tests, 7 of 9 cultures, and 7 of 7 PCR samples
sent were positive for influenza A. Ten patients were treated with an-
tivirals (oseltamivir in 10, + rimantidine in 3). Three patients died
(27%) of progressive pneumonia. Of the two who received antivirals
before death, duration from symptom onset to treatment was a me-
dian of 7.5 days (range 2-15), compared with 7 days (range 1-15) in
those who survived.
Conclusions: S-OIV is a cause of significant morbidity and mor-
tality in HSCT recipients. Patients with cGVHD may be particu-
larly susceptible. Clinical presentation may be subtle and a high
state of vigilance is warranted. The sensitivity of the rapid influenza
test is low. Treatment decisions should be focused on disease risk
and clinical symptoms with confirmation by culture or PCR. Pa-
tients presenting with hypoxemia appeared to have worse out-
comes, and early treatment with antivirals may not abrogate the
severity of disease. Finally, nosocomial infection is a risk, demon-
strating the critical need for rigorous enforcement of infection con-
trol policies.56
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Anti-CMV T-cell count
D1 R1
n5 46
D-R1
n5 31 P value
CMV-specific CD4 T cells
per ml (median) Day 28
1.50 0.10 0.048*
Day 56 5.23 0.56 0.005*
Day 84 8.19 1.27 0.001*
Day 180 6.26 0.32 0.002*
Pp65-specific CD8 T cells
per ml (median) Day 28
0.81 0.03 0.04*
Day 56 12.16 1.49 0.03*
Day 84 11.26 2.77 0.11*
Day 180 3.87 2.67 0.60*
Clinical Outcomes D1 R1
n5 177
D-R1
n5 121
P value
CMV reactivation above
threshold for preemptive therapy
(No. of patients with at least one
reactivation, (%))
36 (20.3%) 58 (48.7%) 0.001**
Recurrent CMV reactivation
(No. of patients with at least 2
reactivations, (%))
7 (3.9%) 19 (15.9%) 0.003**
CMV disease (No. of patients, (%)) 5 (2.8%) 16(13.3%) 0.005**
Death 74 (41.8%) 68 (56.2%) 0.038**
* Univariate analysis (Mann-Whitney-Wilcoxon rank-sum test) ** Multi-
variate analysis (Binomial linear model) including the following covari-
ates: HLA-matched sibling graft, significant graft versus host disease
(GVHD) (grade 2-4 acute or extensive chronic GVHD), disease stage,
donor age, length of follow-up.Background: Anti-CMV T-cells are thought to control CMV. In
seropositive recipients of grafts from seropositive donors (D + R+),
both naı¨ve and memory/effector anti-CMV T-cells are transferred
with the graft. In seropositive recipients of grafts from seronegative
donors (D-R+), only naı¨ve anti-CMVT-cells are transferredwith the
graft. We hypothesized that counts of anti-CMV T-cells are higher
in the D +R+ compared to the D-R+ group, and that this leads to
a lower incidence of CMV complications like CMV disease or
CMV reactivation.
Patients and methods:We reviewed charts of 298 seropositive re-
cipients for CMV reactivation (pp65 antigenemia or CMV DNAe-
mia above institutional threshold for starting preemptive therapy),
recurrent CMV reactivation (above the same threshold), CMV dis-
ease, and death due to any cause. In 77 of these patients, we deter-
mined the counts of anti-CMV effector T-cells (producing INFg
upon 18 h stimulation with CMV lysate in case of CD4 T-cells or
pp65 overlapping peptides in case of CD8 T-cells). Conditioning
of all patients included rabbit-anti-human thymocyte globulin
(Thymoglobulin).
Results: The anti-CMV T cell, in particular, CD4 T-cell counts
were higher, and the cumulative incidences of CMV reactivation, re-
current CMV reactivation, CMV disease and death were lower in
D + R+ compared to D-R+ patients.
Conclusion: Compared to D + R+ patients, D-R+ have lower
counts of anti-CMV T-cells. This appears to translate into a higher
risk of CMV reactivation, CMV disease and lower survival. New
strategies to avoid CMV complications need to be explored for
D-R+ patients, eg, donor vaccination pre-transplant or infusion of
anti-CMV T-cells post-transplant.LATE EFFECTS/QUALITY OF LIFE
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Background: Patients undergoing HCT are at increased of risk
chronic health conditions, including second malignant neoplasms
and cardiovascular disease. Little is known about health behaviors
and cancer screening practices among HCT survivors that could
moderate the risk of these conditions.
Methods: The BMTSS examined health behaviors and cancer
screening practices in individuals who underwent HCT at City of
Hope or University of Minnesota between 1976 and 1998, and sur-
vived 2+ years. Responses from a mailed questionnaire were com-
pared to those obtained from sibling controls. Health behavior was
deemed high-risk if an individual was a current smoker or if they re-
ported risky alcohol intake ($4 drinks/day [males], $3 drinks/day
[females]) on days of alcohol consumption. Questions regarding can-
cer screening practices were tailored to assess adherence to American
Cancer Society guidelines for breast and cervical (females) and testic-
ular (males) cancers.
Results: The study included 1040 survivors: 42.7% underwent al-
logeneic HCT; 43.8% were female; median time from HCT was
7.4 years (range 2.0-27.7 years). Median age at study participation
was 43.8 years (range 18.3-73.0 years) for survivors and 45.2 years
(range 19.3-78.8 years) for siblings (N5 309). Survivors reported
significantly lower rates of high-risk behavior (14.6% v 21.0%;
p\0.01) compared to controls. Adjustment for patient demo-
graphics, SES, diagnosis, HCT-related exposures, and presence
of chronic medical conditions, revealed younger age (\35 years)
at study participation (Odds Ratio [OR]5 5.0; p\0.01), being un-
insured (OR 2.0; p5 0.02), and lower education (\college:
OR5 2.3; p\0.01) to be significantly associated with high-risk be-
havior. HCT survivors reported similar cancer screening practices
when compared to gender-matched sibling controls: Females–
regular self-breast examination (28.9% v 27.0%; p5 0.6), clinical
breast examination (88.4% v 91.3%; p5 0.3), pap smears (85.5%
